1
|
Kemal YN, Demirag GN, Bedir AM, Tomak L, Derebey M, Erdem DL, Gör U, Yücel I. Serum human epididymis protein 4 levels in colorectal cancer patients. Mol Clin Oncol 2017; 7:481-485. [PMID: 28894584 DOI: 10.3892/mco.2017.1332] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Accepted: 07/04/2017] [Indexed: 01/12/2023] Open
Abstract
Tumour markers are widely used for the diagnosis, staging and monitoring of colorectal cancer (CRC) patients in clinical practice. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are the most frequently used biomarkers in CRC patients. A number of studies have recently investigated the presence of human epididymis protein 4 (HE4) overexpression in certain cancer types. Its significance in ovarian and endometrial cancer has been well-demonstrated. The aim of the present study was to evaluate the significance of serum HE4 levels in CRC patients. A total of 46 newly diagnosed CRC patients and 36 age- and gender-matched healthy subjects were included in the study. The concentrations of CEA and CA19-9 were also determined and compared according to HE4 levels. HE4 positivity was determined in 13 of the 46 cases (28.3%) in the CRC group, but no HE4-positive subjects were identified in the control group (0%; P=0.009). The area under the receiver operating characteristic curve for HE4 positivity was 0.641 (95% CI: 0.523-0.760). HE4 was statistically significantly positive in patients with stage III-IV disease and in those with high CA 19-9 levels (all P<0.01). To the best of our knowledge, this is the first study to investigate HE4 expression in CRC patients, and the findings suggest that it may be a useful biomarker, particularly in stage III-IV patients.
Collapse
Affiliation(s)
- Yasemi N Kemal
- Department of Medical Oncology, Samsun Training and Research Hospital, Samsun 55100, Turkey
| | - Guzi N Demirag
- Department of Medical Oncology, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey
| | - Abdulkeri M Bedir
- Department of Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey
| | - Leman Tomak
- Department of Biostatistics, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey
| | - Murat Derebey
- Department of General Surgery, Faculty of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey
| | - Di Lek Erdem
- Department of Medical Oncology, Medical Park Samsun Hospital, Samsun 55200, Turkey
| | - Ufuk Gör
- Department of Biochemistry, Faculty Of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey
| | - Idris Yücel
- Department of Medical Oncology, Faculty Of Medicine, Ondokuz Mayis University, Samsun 55270, Turkey
| |
Collapse
|
2
|
Salis O, Okuyucu A, Bedir A, Gör U, Kulcu C, Yenen E, Kılıç N. Antimetastatic effect of fluvastatin on breast and hepatocellular carcinoma cells in relation to SGK1 and NDRG1 genes. Tumour Biol 2015; 37:3017-24. [PMID: 26419593 DOI: 10.1007/s13277-015-4119-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 09/20/2015] [Indexed: 01/19/2023] Open
Abstract
Metastasis occurs due to migration of the cells from primary tumor toward other tissues by gaining invasive properties. Since metastatic invasion shows a strong resistance against conventional cancer treatments, the studies on this issue have been focused. Within this context, inhibition of migration and determination of the relationships at the gene level will contribute to treatment of metastatic cancer cases. We have aimed to demonstrate the impact of TGF-β1 and fluvastatin on human breast cancer (MCF-7) and human hepatocellular carcinoma (Hep3B) cell cultures via Real-Time Cell Analyzer (RTCA) and to test the expression levels of some genes (NDRG1, SGK1, TWIST1, AMPKA2) and to compare their gene expression levels according to RTCA results. Both of cell series were applied TGF-β1 and combinations of TGF-β1/fluvastatin. Primer and probes were synthesized using Universal Probe Library (UPL, Roche) software, and expression levels of genes were tested via qPCR using the device LightCycler 480 II (Roche). Consequently, fluvastatin dose-dependently inhibited migration induced by TGF-β1 in both groups. This inhibition was accompanied by low level of SGK1 messenger RNA (mRNA) and high levels of NDRG1 and AMPKA2 mRNA. Thus, we conclude that fluvastatin plays an important role in reducing resistance to chemotherapeutics and preventing metastasis.
Collapse
Affiliation(s)
- Osman Salis
- Department of Medical Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Kurupelit, 55139, Samsun, Turkey.
| | - Ali Okuyucu
- Department of Medical Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Kurupelit, 55139, Samsun, Turkey
| | - Abdulkerim Bedir
- Department of Medical Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Kurupelit, 55139, Samsun, Turkey
| | - Ufuk Gör
- Department of Medical Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Kurupelit, 55139, Samsun, Turkey
| | - Canan Kulcu
- Department of Medical Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Kurupelit, 55139, Samsun, Turkey
| | - Eser Yenen
- Department of Medical Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Kurupelit, 55139, Samsun, Turkey
| | - Nermin Kılıç
- Department of Medical Biochemistry, Faculty of Medicine, Ondokuz Mayis University, Kurupelit, 55139, Samsun, Turkey
| |
Collapse
|
3
|
Urbancsek J, Rabe T, Gör U, Schulte B, Grunwald K, Papp Z, Runnebaum B. [Effect of the GnRH analog buserelin on sex hormone serum level in relation to treatment onset and duration]. Geburtshilfe Frauenheilkd 1991; 51:617-25. [PMID: 1834511 DOI: 10.1055/s-2007-1026211] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Changes of serum estradiol, progesterone, LH, FSH, prolactin, testosterone, androstendione, DHEA and DHEAS levels during a GnRH-analogue (buserelin) treatment have been analysed retrospectively taking account of effectiveness of treatment and its relation to the beginning and duration of treatment. 1200 micrograms/day buserelin were administered intranasally from the first day of the menstrual cycle (n = 30) or the 7th hyperthermic day of the cycle (n = 22). The results proved, that the administration of buserelin to sterile women inhibits the ovarian (estradiol, progesterone) and pituitary (LH, FSH) hormone secretion during the first 10-14 days of treatment. The adrenal hormone secretion (DHEA, DHEAS) remained unaffected, whereas the androgens of ovarian origin (testosterone, androstendione) were suppressed during the GnRH analogue treatment. The serum prolactin level increased during the first two weeks of treatment and returned to pretreatment values within the following two weeks. On the basis of the faster suppression of estradiol secretion with buserelin treatment, beginning in the middle of the luteal phase, this therapy is recommended for ovarian suppression.
Collapse
Affiliation(s)
- J Urbancsek
- Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik Heidelberg
| | | | | | | | | | | | | |
Collapse
|